{"id":61152,"date":"2026-03-24T19:53:21","date_gmt":"2026-03-24T11:53:21","guid":{"rendered":"https:\/\/flcube.com\/?p=61152"},"modified":"2026-03-24T19:54:08","modified_gmt":"2026-03-24T11:54:08","slug":"shenzhen-salubris-wins-nmpa-approval-for-sal0150-oral-long-acting-diabetes-obesity-drug-targets-weekly-dosing-regimen","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61152","title":{"rendered":"Shenzhen Salubris Wins NMPA Approval for SAL0150 \u2013 Oral Long-Acting Diabetes\/Obesity Drug Targets Weekly Dosing Regimen"},"content":{"rendered":"\n

Shenzhen Salubris Pharmaceuticals Co., Ltd.<\/strong> (SHE: 002294<\/a>) announced clinical trial approval<\/strong> from China’s National Medical Products Administration (NMPA)<\/strong> for SAL0150<\/strong>, an in-house developed oral long-acting drug<\/strong> for type 2 diabetes mellitus<\/strong>, obesity\/overweight<\/strong>, and type 2 diabetes with peripheral arterial disease<\/strong> (accompanied by intermittent claudication). The candidate aims to achieve once-weekly or less frequent oral dosing<\/strong>, positioning Salubris in the competitive GLP-1\/oral incretin space<\/strong> with potential convenience advantages over current standards.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Approval Type<\/strong><\/td>Clinical trial authorization (IND)<\/td><\/tr>
Product<\/strong><\/td>SAL0150 (oral long-acting innovative drug)<\/td><\/tr>
Developer<\/strong><\/td>Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294)<\/td><\/tr>
Indications<\/strong><\/td>Type 2 diabetes mellitus; obesity\/overweight; T2DM with peripheral arterial disease + intermittent claudication<\/td><\/tr>
Dosing Target<\/strong><\/td>Once weekly or less frequent<\/strong> oral administration<\/td><\/tr>
Approval Date<\/strong><\/td>24\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Therapeutic Goals<\/h2>\n\n\n\n
Attribute<\/th>SAL0150 Specification<\/th><\/tr><\/thead>
Route<\/strong><\/td>Oral<\/strong> (vs. injectable GLP-1 agonists)<\/td><\/tr>
Dosing Frequency<\/strong><\/td>Long-acting<\/strong> \u2013 targeting once-weekly or extended intervals<\/td><\/tr>
Primary Indications<\/strong><\/td>Glycemic control (T2DM); weight management (obesity\/overweight); vascular complications (peripheral arterial disease)<\/td><\/tr>
Expected Benefits<\/strong><\/td>Good therapeutic efficacy on metabolic and cardiovascular endpoints<\/strong>; favorable safety profile<\/strong><\/td><\/tr>
Development Status<\/strong><\/td>NMPA IND approval; Phase I\/II initiation imminent<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context & Competitive Landscape<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
China Diabetes\/Obesity Market<\/strong><\/td>~140 million T2DM patients<\/strong>; 50%+ overweight\/obesity<\/strong>; RMB 100+ billion<\/strong> annual drug market growing at 15% CAGR<\/td><\/tr>
GLP-1 Oral Gap<\/strong><\/td>Oral semaglutide (Rybelsus) daily dosing; no approved weekly oral<\/strong> incretin in China \u2013 significant unmet need for convenience<\/td><\/tr>
SAL0150 Differentiation<\/strong><\/td>Once-weekly oral<\/strong> would disrupt injectable GLP-1 dominance (semaglutide, tirzepatide) and challenge daily oral alternatives<\/td><\/tr>
Peripheral Arterial Disease (PAD)<\/strong><\/td>30\u201350% of T2DM patients<\/strong> develop PAD; intermittent claudication indication addresses cardiovascular-metabolic convergence<\/strong> \u2013 differentiated vs. pure weight-loss focus<\/td><\/tr>
Competitive Landscape<\/strong><\/td>Oral GLP-1s in development: Orforglipron (Eli Lilly, Phase III), AZD5004 (AstraZeneca); SAL0150’s weekly frequency + PAD indication<\/strong> provides positioning niche<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n